

<b>Reference:</b>	FOI.15023.24
<b>Subject:</b>	Treatment of facial angiofibroma
<b>Date of Request:</b>	8 August 2024

**Requested:**

1. Please provide the number of patients on the Unlicensed Sirolimus Ointment for the treatment of facial angiofibroma associated with tuberous sclerosis.
2. Out of the patients on the Unlicensed Sirolimus Ointment for the treatment of facial angiofibroma associated with tuberous sclerosis, how many patients are on the 0.1%, 0.2% and 0.5% strength.

**Response:**

1. & 2. Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. Therefore, the UHB is withholding these details under Section 40(2) of the Freedom of Information Act 2000 (FoIA).

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.